Global Oncology Adjuvants Market Size, Share & Trends Analysis Report, By Type (Hormone Therapy, Radiotherapy, Targeted Therapy, Chemotherapy, Immunotherapy, and Others), By Application (Hospitals, Cancer Research Institutes, and Others), Forecast (2022-2028)

The global oncology adjuvants market is anticipated to grow at a CAGR of 7.0% during the forecast period (2022-2028). Oncology adjuvants are defined as additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. This form of treatment is mainly focused on to reducing the reoccurrence of cancer. The major factor attributable to the market growth includes the growing incidence and prevalence of cancer coupled with the increasing cases of reoccurrence of various forms of cancer. Another key benefit offered by the oncology adjuvant therapy is that it increases the chances of survival patients having cancer by eliminating the risk of cancer reoccurrence. In addition to this, these adjuvant therapies are used in the treatment of lung cancer, colon cancer, prostate, breast cancer, and other forms of gynecological cancers among various other forms of cancers.

 

Furthermore, the growing trend of personalized medicine also supports the concept of oncology adjuvants therapy. It is noticed that several aspects are taken into consideration by the oncologists including the individual statistical data of the patients prior to opting for suitable adjuvant therapy. This personalized form of treatment provides better chances of reducing the reoccurrence of cancer and increasing the survival rate of patients. Thus, such factors are also anticipated to augment the growth of the global oncology adjuvants market during the forecast period.

 

 

Some key players operating in the market include Sanofi S.A., Pfizer Inc., and Eli Lilly & Co., among others. The market players are focusing on several strategies, such as mergers and acquisitions, partnerships, product launches, and collaborations, among others. For instance, in October 2021, the US Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Sanofi S.A., Pfizer Inc., and Eli Lilly & Co., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Oncology Adjuvants Market Report by Segment

By Type

• Hormone Therapy
• Radiotherapy
• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

By Application

• Hospitals
• Cancer Research Institutes
• Others

Global Oncology Adjuvants Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

 

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

 

Rest of the World

• Latin America
• Middle East and Africa